We interrogated the AML data cohort of TCGA and GTEx in GEPIA2 platform and observed significant downregulation of SF3B5 and SNRPB in AML patients compared to control (one-way ANOVA, p < 0.01) (Figure 5H). This evidence concerns the gene SF3B5 and acute myeloid leukemia.